PharmaShots | Incisive News in 3 Shots

Subscribe Now

mcrpc

Novartis’ Pluvicto (177Lu-PSMA-617) Received the US FDA’s Approval as the First Targeted Radioligand Therapy for Progressive, PSMA Positive mCRPC

Novartis’ Pluvicto (177Lu-PSMA-617) Received the US FDA’s Approval as the First Targeted Radioligand Therapy for Progressive, PSMA...

March 23, 2022

Bristol-Myers (BMS) Reports Results of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-II CheckMate -650 trial for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Bristol-Myers (BMS) Reports Results of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-II CheckMate -650 trial for Metastatic Castra...

February 15, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us